Abstract
Nebivolol is a novel beta1-blocker with a nitric oxide (NO)--potentiating, vasodilatory effect that is unique among beta-blockers. It was already shown that nebivolol ameliorates atherosclerosis in cholesterol-fed rabbits. We, therefore, wanted to investigate whether this is the case in the fine experimental model of atherosclerosis: apolipoprotein E (apoE)-knockout mice. Nebivolol attenuated atherogenesis, measured both by "en face" method (9.23+/-1.8% vs. 14.6+/-2.1%) and "cross-section" method (63125+/-8455 microm(2) vs. 91416+/-8357 m(2)). This is the first report showing the effect of nebivolol on atherogenesis in gene-targeted mice.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adrenergic beta-1 Receptor Antagonists*
-
Adrenergic beta-Antagonists / therapeutic use*
-
Animals
-
Aorta / drug effects
-
Aorta / pathology
-
Apolipoproteins E / deficiency
-
Apolipoproteins E / genetics
-
Atherosclerosis / blood
-
Atherosclerosis / drug therapy*
-
Atherosclerosis / pathology
-
Benzopyrans / therapeutic use*
-
Cholesterol / blood
-
Ethanolamines / therapeutic use*
-
Female
-
Mice
-
Mice, Knockout
-
Nebivolol
-
Severity of Illness Index
-
Triglycerides / blood
-
Vasodilator Agents / therapeutic use*
Substances
-
Adrenergic beta-1 Receptor Antagonists
-
Adrenergic beta-Antagonists
-
Apolipoproteins E
-
Benzopyrans
-
Ethanolamines
-
Triglycerides
-
Vasodilator Agents
-
Nebivolol
-
Cholesterol